ClinicalTrials.gg
Active, not recruitingNCT04464226DARO ROLL OVERUpdated Oct 28, 2026

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

A Phase 3 interventional study of Darolutamide (Nubeqa, BAY1841788) in Cancer, sponsored by Bayer. Active, not recruiting at 335 sites in 39 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Bayer · Phase 3, Interventional, and Other

Updated Oct 28, 2026Enrollment updated51 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
774
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Roll-Over Study
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's planned enrollment of 774 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Participants enrolled in any Bayer-sponsored darolutamide feeder study at the time of study closure or primary completion, who are currently receiving darolutamide and are experiencing clinical benefit from treatment.
  • Participants who have not met any treatment discontinuation criteria in the feeder study protocol.
  • Willingness to continue practicing acceptable methods of during the study.

Exclusion criteria

Exclusion Criteria:

  • Participant is unable to comply with the requirements of the study.
  • Negative benefit/ risk ratio as determined by the investigator.
  • Meet any criteria for treatment discontinuation of the feeder study the participant is coming from.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
774 participants (estimated)

Study arms

  • Experimental
    Darolutamide (BAY1841788)

    Participants enrolled in the current study will use the dose they were assigned to in the feeder study they come from.

    Drug: Darolutamide (Nubeqa, BAY1841788)

Interventions

  • Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.

    Also known as: ODM-201

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 4 years

  2. Incidence of treatment-emergent serious adverse events (TESAEs)

    Time frame: Up to 4 years

  3. Incidence of drug-related TEAEs

    Time frame: Up to 4 years

  4. Incidence of drug-related TESAEs

    Time frame: Up to 4 years

Secondary outcomes

  1. Number of dose modifications

    Time frame: Up to 4 years

07

Study locations

335 sites

Showing the first 100 of 335 sites across 39 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Jun 2028, 92 months after the start.

Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's planned 92 months is above that.

Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2020
First posted
Jul 9, 2020
StartActual
Oct 20, 2020
Primary completionEst.
Jun 26, 2028
CompletionEst.
Jun 26, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
51 sites added, 51 sites removed
Show 51 added (12 United Kingdom, 7 Ukraine, 6 South Korea, 5 Brazil, 5 Poland, 3 Canada, 3 Israel, 2 China, 2 Romania, 2 Spain, 1 United States, 1 Czechia, 1 France, 1 Latvia)
  • VCU Health Ambulatory Care Center - Cardiology · Richmond, United States
  • Instituto do Cancer do Estado de Sao Paulo · São Paulo, Brazil
  • Hospital São Rafael · São Paulo, Brazil
  • Santa Casa de Misericórdia da Bahia · São Paulo, Brazil
  • Irmandade Santa Casa de Misericordia de Porto Alegre | Oncology · São Paulo, Brazil
  • União Bras. de Edu. e Assist. Hospital São Lucas da PUCRS · São Paulo, Brazil
  • Sunnybrook Health Sciences Centre | Oncology · Toronto, Canada
  • Princess Margaret Cancer Centre | Oncology · Toronto, Canada
  • Centre hospitalier universitaire de Sherbrooke (CHUS) | Oncology · Sherbrooke, Canada
  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School · Nanjing, China
  • Qilu Hospital of Shandong University · Jinan, China
  • Fakultní nemocnice Kralovské Vinohrady · Prague, Czechia
  • CHU Poitiers - Hopital de la Miletrie · Poitiers, France
  • Rabin Medical Center | Beilinson Campus · Petah Tikva, Israel
  • Ziv Medical Center · Safed, Israel
  • Clalit Health | Soroka Medical Center · Beersheba, Israel
  • Litavniece Dzintra practice in urology and oncological chem. · Liepāja, Latvia
  • Velocity Clinical Research Lublin · Lublin, Poland
  • Europejskie Centrum Zdrowia Otwock, Szpital im. F. Chopina · Otwock, Poland
  • Urologica Praktyka Lekarska Adam Marcheluk · Siedlce, Poland
  • Szpital Grochowski im. dr.med. Rafała Masztaka · Warsaw, Poland
  • ETG Network Spolka z o.o. · Lodz, Poland
  • Institutul Clinic Fundeni, sectia Nefrologie Clinica · Bucharest, Romania
  • Spitalul Clinic Judetean Mures · Târgu Mureş, Romania
  • Kyungpook National University Chilgok Hospital | Urology · Daegu, South Korea
  • Chonnam National University Hospital | Urology · Gwangju, South Korea
  • Seoul National University Hospital | Urology · Seoul, South Korea
  • Severance Hospital | Urology · Seoul, South Korea
  • Samsung Medical Center | Urology · Seoul, South Korea
  • Seoul St Mary's Hospital | Urology · Seoul, South Korea
  • …and 21 more on the registry record
Show 51 removed
  • VCU Health Ambulatory Care Center - Cardiology · Virginia, United States
  • Instituto do Cancer do Estado de Sao Paulo · São Paulo, Brazil
  • Hospital São Rafael · São Paulo, Brazil
  • Santa Casa de Misericórdia da Bahia · São Paulo, Brazil
  • Irmandade Santa Casa de Misericordia de Porto Alegre | Oncology · São Paulo, Brazil
  • União Bras. de Edu. e Assist. Hospital São Lucas da PUCRS · São Paulo, Brazil
  • Sunnybrook Health Sciences Centre · Toronto, Canada
  • Princess Margaret Hospital-University Health Network · Toronto, Canada
  • Centre hospitalier universitaire de Sherbrooke (CHUS) | Oncology · Granby, Canada
  • NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School · Nanjing, China
  • Qilu Hosp., Shandong Univ. · Jinan, China
  • Fakultni nemocnice Kralovske Vinohrady · Prague, Czechia
  • Hôpital de la Milétrie · Poitiers, France
  • Clalit Health | Soroka Medical Center- Nephrology Department · Beersheba, Israel
  • Rabin Medical Center | Beilinson Hospital - Nephrology and Hypertension Institute · Petah Tikva, Israel
  • Health Corporation of the Ziv Medical Center (R.A.) · Safed, Israel
  • Litavniece Dzintra practice in urology and oncological chem. · Liepāja, Latvia
  • ETG Network Spolka z o.o. · Lodz, Poland
  • Velocity Clinical Research Lublin · Lublin, Poland
  • Europejskie Centrum Zdrowia Otwock, Szpital im. F. Chopina · Otwock, Poland
  • Urologica Praktyka Lekarska Adam Marcheluk · Siedlce, Poland
  • Szpital Grochowski im. dr.med. Rafala Masztaka · Warsaw, Poland
  • Spitalul Clinic Judetean Mures · Târgu Mureş, Romania
  • Institutul Clinic Fundeni, sectia Nefrologie Clinica · Bucharest, Romania
  • Chonnam National University Hospital | Urology · Gwangju, South Korea
  • Kyungpook National University Chilgok Hospital · Daegu, South Korea
  • Seoul National University Hospital-Department of Urology · Seoul, South Korea
  • Severance Hospital, Yonsei University Health System · Seoul, South Korea
  • Samsung Medical Center - Urology · Seoul, South Korea
  • The Catholic University of Korea Seoul St. Mary's Hospital · Seoul, South Korea
  • …and 21 more on the registry record
Oct 28, 2026
Enrollment
402→774
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    51 sites added, 51 sites removed
    Show 51 added (12 United Kingdom, 7 Ukraine, 6 South Korea, 5 Brazil, 5 Poland, 3 Canada, 3 Israel, 2 China, 2 Romania, 2 Spain, 1 United States, 1 Czechia, 1 France, 1 Latvia)
    • VCU Health Ambulatory Care Center - Cardiology · Richmond, United States
    • Instituto do Cancer do Estado de Sao Paulo · São Paulo, Brazil
    • Hospital São Rafael · São Paulo, Brazil
    • Santa Casa de Misericórdia da Bahia · São Paulo, Brazil
    • Irmandade Santa Casa de Misericordia de Porto Alegre | Oncology · São Paulo, Brazil
    • União Bras. de Edu. e Assist. Hospital São Lucas da PUCRS · São Paulo, Brazil
    • Sunnybrook Health Sciences Centre | Oncology · Toronto, Canada
    • Princess Margaret Cancer Centre | Oncology · Toronto, Canada
    • Centre hospitalier universitaire de Sherbrooke (CHUS) | Oncology · Sherbrooke, Canada
    • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School · Nanjing, China
    • Qilu Hospital of Shandong University · Jinan, China
    • Fakultní nemocnice Kralovské Vinohrady · Prague, Czechia
    • CHU Poitiers - Hopital de la Miletrie · Poitiers, France
    • Rabin Medical Center | Beilinson Campus · Petah Tikva, Israel
    • Ziv Medical Center · Safed, Israel
    • Clalit Health | Soroka Medical Center · Beersheba, Israel
    • Litavniece Dzintra practice in urology and oncological chem. · Liepāja, Latvia
    • Velocity Clinical Research Lublin · Lublin, Poland
    • Europejskie Centrum Zdrowia Otwock, Szpital im. F. Chopina · Otwock, Poland
    • Urologica Praktyka Lekarska Adam Marcheluk · Siedlce, Poland
    • Szpital Grochowski im. dr.med. Rafała Masztaka · Warsaw, Poland
    • ETG Network Spolka z o.o. · Lodz, Poland
    • Institutul Clinic Fundeni, sectia Nefrologie Clinica · Bucharest, Romania
    • Spitalul Clinic Judetean Mures · Târgu Mureş, Romania
    • Kyungpook National University Chilgok Hospital | Urology · Daegu, South Korea
    • Chonnam National University Hospital | Urology · Gwangju, South Korea
    • Seoul National University Hospital | Urology · Seoul, South Korea
    • Severance Hospital | Urology · Seoul, South Korea
    • Samsung Medical Center | Urology · Seoul, South Korea
    • Seoul St Mary's Hospital | Urology · Seoul, South Korea
    • …and 21 more on the registry record
    Show 51 removed
    • VCU Health Ambulatory Care Center - Cardiology · Virginia, United States
    • Instituto do Cancer do Estado de Sao Paulo · São Paulo, Brazil
    • Hospital São Rafael · São Paulo, Brazil
    • Santa Casa de Misericórdia da Bahia · São Paulo, Brazil
    • Irmandade Santa Casa de Misericordia de Porto Alegre | Oncology · São Paulo, Brazil
    • União Bras. de Edu. e Assist. Hospital São Lucas da PUCRS · São Paulo, Brazil
    • Sunnybrook Health Sciences Centre · Toronto, Canada
    • Princess Margaret Hospital-University Health Network · Toronto, Canada
    • Centre hospitalier universitaire de Sherbrooke (CHUS) | Oncology · Granby, Canada
    • NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School · Nanjing, China
    • Qilu Hosp., Shandong Univ. · Jinan, China
    • Fakultni nemocnice Kralovske Vinohrady · Prague, Czechia
    • Hôpital de la Milétrie · Poitiers, France
    • Clalit Health | Soroka Medical Center- Nephrology Department · Beersheba, Israel
    • Rabin Medical Center | Beilinson Hospital - Nephrology and Hypertension Institute · Petah Tikva, Israel
    • Health Corporation of the Ziv Medical Center (R.A.) · Safed, Israel
    • Litavniece Dzintra practice in urology and oncological chem. · Liepāja, Latvia
    • ETG Network Spolka z o.o. · Lodz, Poland
    • Velocity Clinical Research Lublin · Lublin, Poland
    • Europejskie Centrum Zdrowia Otwock, Szpital im. F. Chopina · Otwock, Poland
    • Urologica Praktyka Lekarska Adam Marcheluk · Siedlce, Poland
    • Szpital Grochowski im. dr.med. Rafala Masztaka · Warsaw, Poland
    • Spitalul Clinic Judetean Mures · Târgu Mureş, Romania
    • Institutul Clinic Fundeni, sectia Nefrologie Clinica · Bucharest, Romania
    • Chonnam National University Hospital | Urology · Gwangju, South Korea
    • Kyungpook National University Chilgok Hospital · Daegu, South Korea
    • Seoul National University Hospital-Department of Urology · Seoul, South Korea
    • Severance Hospital, Yonsei University Health System · Seoul, South Korea
    • Samsung Medical Center - Urology · Seoul, South Korea
    • The Catholic University of Korea Seoul St. Mary's Hospital · Seoul, South Korea
    • …and 21 more on the registry record
    Enrollment 402→774
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04464226
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 9, 2020
Start date
Oct 20, 2020
Primary completion
Jun 26, 2028 (estimated)
Completion
Jun 26, 2028 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion